TOKYO -- Japanese brewer Kirin Holdings will spend 7.7 billion yen ($73 million) to raise production of an ingredient found in drugs used to treat brain disease and in health supplements, as the company shifts its focus in response to the aging of its home market.
Its Kyowa Hakko Bio subsidiary will expand its factory in Japan's western Yamaguchi Prefecture, with additional production expected to begin in the summer of 2023. The expansion will raise its capacity two and a half times from the current level.
